Research programme: Alzheimer's disease vaccine intranasal - ID Pharma
Alternative Names: Alzheimer's disease vaccine intranasal research programme - ID PharmaLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator DNAVEC Corporation; National Institute for Longevity Sciences
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Japan (Intranasal)
- 25 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's Disease pharmacodynamics section
- 20 Jun 2005 Preclinical trials in Alzheimer's disease in Japan (Intranasal)